09:54 AM EST, 02/12/2025 (MT Newswires) -- Grail (GRAL) is making its Galleri multicancer early detection test directly available to physicians in the US through its collaboration with Quest Diagnostics ( DGX ) , the companies said Wednesday.

The companies said the test can now be ordered from Grail through Quest's connectivity system, helping streamline the process of ordering for physicians.

The integration of Grail's test into Quest's connectivity system will also increase availability by making the test accessible to patients at any Quest patient access point, the companies said.

Financial details of the collaboration weren't provided.

Price: 33.01, Change: -0.14, Percent Change: -0.42